Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Abstract Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease. In a phase 2b dose-ranging study o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Paul Emery, Patrick Durez, Axel J. Hueber, Inmaculada de la Torre, Esbjörn Larsson, Thorsten Holzkämper, Yoshiya Tanaka
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2021-01-01
Edice:	Arthritis Research & Therapy
Témata:	Rheumatoid arthritis Baricitinib Radiographic progression Joint damage Joint erosion
On-line přístup:	https://doi.org/10.1186/s13075-020-02379-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!